Venlafaxine Hydrochloride
Brand Names: Effexor
Methodology & AI Transparency ⓘ
Venlafaxine Hydrochloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Venlafaxine hydrochloride extended-release capsules are indicated in adults for the treatment of: Major Depressive Disorder (MDD) Generalized Anxiety Disorder (GAD) Social Anxiety Disorder (SAD) Panic Disorder (PD) Venlafaxine hydrochloride extended-release capsules are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with: Major Depressive Disorder ( MDD ) ( 1 ) Generalized Anxiety Disorder ( GAD ) ( 1 ) Social Anxiety Disorder ( SAD ) ( 1 ) Panic Disorder ( PD ) ( 1 )
- 2 Real-world patient consensus: Tracked across 10 patient dosage logs with a 90% satisfaction benchmark (RxCUI 313581).
- 3 Typical cash cost range: Public pharmacy ledger: $5.86 low cash benchmark vs. $34.50 chain retail average ($6.1844/unit CMS NADAC).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Venlafaxine Hydrochloride: nausea (10%), somnolence (5%), dry mouth (7%).
Ask our AI Specialists anything about Venlafaxine Hydrochloride
Venlafaxine Hydrochloride Mechanism, CYP450 Pathways & DailyMed Monograph
Venlafaxine hydrochloride extended-release capsules are indicated in adults for the treatment of: Major Depressive Disorder (MDD) Generalized Anxiety Disorder (GAD) Social Anxiety Disorder (SAD) Panic Disorder (PD) Venlafaxine hydrochloride extended-release capsules are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with: Major Depressive Disorder ( MDD ) ( 1 ) Generalized Anxiety Disorder ( GAD ) ( 1 ) Social Anxiety Disorder ( SAD ) ( 1 ) Panic Disorder ( PD ) ( 1 )
12.1 Mechanism of Action The mechanism of action of venlafaxine in the treatment of MDD, GAD, SAD, and PD is unclear, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake.
Pharmacokinetic profiling of Venlafaxine Hydrochloride demonstrates an elimination half-life of Terminal t½ estimated at 4–14 hrs depending on renal/hepatic reserve (Venlafaxine Hydrochloride) with F ≈ 75%–87% systemic availability after standard oral Venlafaxine Hydrochloride administration systemic bioavailability; clearance proceeds via mixed metabolic conjugation and unchanged urinary excretion across venlafaxine hydrochloride regimens, reaching clinical onset within time to peak concentration spans 1 to 3 hrs under venlafaxine hydrochloride maintenance.
Titration schedules for Venlafaxine Hydrochloride (150 mg/1 Capsule, Extended Release → 75 mg/1 Capsule, Extended Release → 37.5 mg/1 Capsule, Extended Release → 37.5 mg/1 Tablet → 75 mg/1 Tablet) require excluding severe drug-induced hypersensitivity to venlafaxine hydrochloride or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2026-03-23 for venlafaxine hydrochloride; real-world patient logs highlight nausea (10% of reports), headache (7.4% of reports), dry mouth (7% of reports) alongside a 90.00% Worth-It consensus.
Assess baseline hepatic panels and interacting prescriptions when starting Venlafaxine Hydrochloride (serotonin and norepinephrine reuptake inhibitor).
Botanical enzyme modulators may alter oral first-pass exposure of Venlafaxine Hydrochloride; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Venlafaxine Hydrochloride or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2026-03-23 for Venlafaxine Hydrochloride
Logged Side-Effect Incidence (10 Reports)
Venlafaxine Hydrochloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Venlafaxine Hydrochloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy and tolerability of antidepressant drugs in treatment of depression in: What a 6,949-Participant Study Found A total of 33 RCTs were included in 32 articles, involving 6949 patients. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences • 2022-08-01 • Meta-Analysis | N = 6,949 | 99/100 | PMID 37202104 ↗ |
| Which Antidepressant Gives You the Best Shot at Full Recovery? What a Major Review Found These results indicate that venlafaxine therapy is statistically superior to SSRIs as a class, but only to fluoxetine individually. Biological psychiatry • 2008-02-15 • Meta-Analysis | N = 3,621 | 99/100 | PMID 17888885 ↗ |
| New Insights on Efficacy, tolerability, and acceptability of bupropion for: What a 1,117-Participant Study Found According to the limited data obtained from three RCTs, bupropion XL is as effective and tolerable as venlafaxine XR for adult patients with MDD. Drug design, development and therapy • 2013-01-15 • Meta-Analysis | N = 1,117 | 94/100 | PMID 24101861 ↗ |
| What the Latest Evidence Really Says About Specificity profile of venlafaxine and sertraline in major depression: Our results could represent an interesting point of view in the perspective of choosing the most suitable therapy based on clinical and social features for each patient. The international journal of neuropsychopharmacology • 2014-01-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 23953038 ↗ |
| Can This Approach Help? Inside the Latest Research on A randomized, double-blinded, compared against a dummy pill (placebo) study to Venlafaxine ER has a favorable benefit-risk profile in adult Japanese patients with GAD, indicating its potential to improve GAD symptoms as well as patients' function and exert superior anxiolytic effects over placebo without... Psychiatry and clinical neurosciences • 2025-12-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 41123332 ↗ |
Venlafaxine Hydrochloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $6.1844/unit (~$185.53/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $5.86 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 10 Anonymous DotMD Community Micro-Logs | $7.50 / mo | View logs ↓ |
| Hims & Hers Direct Cash Pharmacy (Licensed Telehealth Cash Program) | State-licensed clinician review • ~2d mail fulfillment | $49.00/mo program | Program details |
| Sesame Direct Cash-Pay Prescriber Network (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $29.00 consult | Program details |
Venlafaxine Hydrochloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Venlafaxine Hydrochloride RxNorm Concept ID | 313581 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $6.1844 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $5.86 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 90.00% Worth It (10 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Venlafaxine Hydrochloride Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Venlafaxine Hydrochloride integrating DailyMed SPL (2026-03-23), CMS NADAC ($6.1844/unit), and 10 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Venlafaxine Hydrochloride community threads and patient logs by age, biological sex, dosage, and treatment duration.